Brian Adams - 03 Sep 2025 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Legal Officer
Signature
/s/ Bruce Jacobs, as Attorney-in-Fact
Issuer symbol
KYMR
Transactions as of
03 Sep 2025
Net transactions value
$0
Form type
4
Filing time
03 Sep 2025, 17:05:04 UTC
Previous filing
30 Jul 2025
Next filing
04 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Adams Brian Chief Legal Officer C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN /s/ Bruce Jacobs, as Attorney-in-Fact 03 Sep 2025 0001636994

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Award $0 +52,500 $0.000000 52,500 03 Sep 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 +105,000 $0.000000 105,000 03 Sep 2025 Common Stock 105,000 $43.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following September 3, 2025, subject to the reporting person's continued employment through each vesting date.
F2 Twenty-five percent (25%) of the shares underlying this stock option shall vest on September 3, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.